Pyxis Oncology, Inc. Investment Income, Net
Pyxis Oncology, Inc. (PYXS) reported Investment Income, Net of $255.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-13
- Pyxis Oncology, Inc. investment income, net for the quarter ending 2026-06-30 was $255.00K, a 74.37% decline year-over-year.
- Pyxis Oncology, Inc. investment income, net for the quarter ending 2026-03-31 was $457.00K, a 63.17% decline year-over-year.
- Pyxis Oncology, Inc. investment income, net for the quarter ending 2025-12-31 was $600.00K, a 62.96% decline year-over-year.
- Pyxis Oncology, Inc. investment income, net for the quarter ending 2025-09-30 was $774.00K, a 58.07% decline year-over-year.
- Pyxis Oncology, Inc. investment income, net for fiscal 2025 was $3.61M, a 48.71% decline from fiscal 2024.
- Pyxis Oncology, Inc. investment income, net for fiscal 2024 was $7.04M, a 6.17% increase from fiscal 2023.
- Pyxis Oncology, Inc. investment income, net for fiscal 2023 was $6.63M, a 139.87% increase from fiscal 2022.
- Pyxis Oncology, Inc. investment income, net for fiscal 2022 was $2.76M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $255.00K 10-Q · filed 2026-08-13 | $712.00K 10-Q · filed 2026-08-13 | $1.31M derived: sum of 3 quarters · filed 2026-08-13 | $2.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $457.00K 10-Q · filed 2026-05-14 | $1.06M derived: sum of 2 quarters · filed 2026-05-14 | $1.83M derived: sum of 3 quarters · filed 2026-05-14 | $2.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.37M derived: sum of 2 quarters · filed 2026-03-23 | $2.37M derived: sum of 3 quarters · filed 2026-08-13 | $3.61M 10-K · filed 2026-03-23 |
| 2025-09-30 | $774.00K 10-Q · filed 2025-11-03 | $1.77M derived: sum of 2 quarters · filed 2026-08-13 | $3.01M 10-Q · filed 2025-11-03 | $4.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $995.00K 10-Q · filed 2026-08-13 | $2.24M 10-Q · filed 2026-08-13 | $3.86M derived: sum of 3 quarters · filed 2026-08-13 | $5.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-14 | $2.86M derived: sum of 2 quarters · filed 2026-05-14 | $4.71M derived: sum of 3 quarters · filed 2026-05-14 | $6.73M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.47M derived: sum of 2 quarters · filed 2026-03-23 | $5.49M derived: sum of 3 quarters · filed 2026-03-23 | $7.04M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-03 | $3.87M derived: sum of 2 quarters · filed 2025-11-03 | $5.42M 10-Q · filed 2025-11-03 | $7.01M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $2.02M 10-Q · filed 2025-08-14 | $3.57M 10-Q · filed 2025-08-14 | $5.17M derived: sum of 3 quarters · filed 2025-08-14 | $6.87M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.55M 10-Q · filed 2025-05-15 | $3.14M derived: sum of 2 quarters · filed 2025-05-15 | $4.85M derived: sum of 3 quarters · filed 2025-05-15 | $6.51M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $3.30M derived: sum of 2 quarters · filed 2025-03-18 | $4.96M derived: sum of 3 quarters · filed 2025-03-18 | $6.63M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.71M 10-Q · filed 2024-11-12 | $3.36M derived: sum of 2 quarters · filed 2024-11-12 | $5.04M 10-Q · filed 2024-11-12 | $6.91M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.66M 10-Q · filed 2024-08-14 | $3.33M 10-Q · filed 2024-08-14 | $5.20M derived: sum of 3 quarters · filed 2024-08-14 | $5.92M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-14 | $3.54M derived: sum of 2 quarters · filed 2024-05-14 | $4.26M derived: sum of 3 quarters · filed 2024-05-14 | $4.43M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.59M derived: sum of 2 quarters · filed 2024-03-21 | $2.75M derived: sum of 3 quarters · filed 2024-03-21 | $2.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | $719.00K 10-Q · filed 2023-11-07 | $883.00K derived: sum of 2 quarters · filed 2023-11-07 | $892.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $164.00K 10-Q · filed 2023-08-11 | $173.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $9.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |